Last reviewed 2026-04-23 · How we verify

TCA108

TCA108 is a small molecule that targets the PI3K/AKT/mTOR pathway.

TCA108 is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Advanced solid tumors with PI3K pathway alterations.

At a glance

Mechanism of action

TCA108 works by inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT/mTOR pathway, which is involved in cell growth and survival. This inhibition leads to a decrease in the activity of AKT and mTOR, resulting in anti-tumor effects.

Approved indications

• Advanced solid tumors with PI3K pathway alterations

Common side effects

• Hyperglycemia
• Diarrhea
• Nausea
• Fatigue
• Anemia

Key clinical trials

• A Study to Investigate Efficacy and Safety of a TCA108 in Participants ≥18 Years With Uncontrolled Hypertension (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.